Health Condition 1: H101- Acute atopic conjunctivitis
Conditions
Interventions
Intervention1: Chloroquine: 0.03% Chloroquine phosphate drops + 0.1% Olopatadine drops twice a day
for 1 year
Control Intervention1: Olopatadine: 0.1% Olopatadine drops + 0.5% Carboxy methyl cellulos
Sponsors
RP Centre
Eligibility
Inclusion criteria
Inclusion criteria: All patients attending the outpatient department with clinically diagnosed allergic eye disease based on signs (itching, watering) and symptoms (conjunctival hyperemia, palpebral hypertrophy) will participate in the study. No other methods of diagnosis will be considered besides clinical signs and symptoms.
Exclusion criteria
Exclusion criteria: 1. Uveitis, conjunctivitis and other ocular pathologies 2. Bronchial asthma, eczema 3. History of dry eye, blepharitis, contact lens use 4. Receiving topical or systemic medications 5. History of sensitivity to any constituents of the eye drops
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in ocular symptoms including eye itching and rubbing Timepoint: 1 week, 4 weeks, 2 months, 3 months, 6 months, 9 months, 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| Alterations in Inflammatory markers in tear film(Alpha- Antitrypsin, MMP9, IL-1, IL-8, IFN gamma)Timepoint: 4 weeks, 3 months, 6 months, 9 months, 1 year | — |
Countries
India
Contacts
Public ContactNamrata Sharma
Dr. Rajendra Prasad Centre for Ophthalmic Sciences AIIMS New Delhi
Outcome results
None listed